Glaxo to correct statements on Zantac
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.GLAXO confirmed yesterday that it would write to several thousand American doctors to correct misleading claims about its ulcer treatment, Zantac. A spokesman said that the terms of the letter had been agreed with the Food and Drug Administration, the industry watchdog in the US, but refused to say when it would be sent out.
Glaxo will also take out advertisements in medical journals in order to placate the FDA, a powerful regulator that has the power to approve and ban sales of drugs in the US, the world's biggest market for pharmaceuticals.
The embarrassing admission that Glaxo had misled doctors follows a letter from the FDA in January, which suggested that the company's promotional materials 'frequently suggest unapproved uses for Zantac and consistently make comparative efficacy and safety claims that are not supported by adequate data.'
The letter said Glaxo's claim that Zantac was equally effective in smokers and non-smokers was made on the basis of inadequate studies. It said Glaxo should make explicit the approved indications for the drug and criticised Glaxo's suggestions that Zantac is safer than rival treatments such as SmithKline Beecham's Tagamet.
The company tried to play down the significance of the climb-down but Glaxo's shares are likely to come under renewed pressure today. Sales of Zantac represent nearly half of Glaxo's turnover, making it the world's best-selling drug. In the year to June 1992 profits from Zantac exceeded pounds 1bn for the first time.
Worries about the threat from cheaper generic rivals have already contributed to a 25 per cent fall in Glaxo's share price this year from 793p to 597p. The resignation of the chief executive, Ernest Mario, earlier this month further unsettled the company. Glaxo said yesterday that Dr Mario's departure was unrelated to the disagreement with the FDA.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments